Arum Kim

Arum Kim

Auto-generated profile, based on publicly available information

Arum Kim

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Lung Cancer
Verified
Journal Article
Closed access
EKEun Young Kim
Eun Young Kim
AKArum Kim
Arum Kim
SKSe Kyu Kim
Se Kyu Kim
YCYoon Soo Chang
Yoon Soo Chang

1 January 2022 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
JLJung Mo Lee
Jung Mo Lee
HKHyoSoo Kim
HyoSoo Kim
AKArum Kim
Arum Kim
YCYoon Soo Chang
Yoon Soo Chang
JLJin Gu Lee
Jin Gu Lee
EKEun Young Kim
Eun Young Kim
Lee JM, et al. Yonsei Med J. 2022 Jan;63(1):16-25. https://doi.org/10.3349/ymj.2022.63.1.16

1 August 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
JFJulia Fehniger
Julia Fehniger
ABAllison L. Brodsky
Allison L. Brodsky
AKArum Kim
Arum Kim
BPBhavana Pothuri
Bhavana Pothuri
Medical marijuana (MM) use is common among cancer patients, but relatively little is known about the usage patterns and efficacy of MM used by gynecologic cancer patients. Demographic and clinical data were collected for gynecologic cancer patients prescribed MM between May 2016 and February 2019. The electronic medical record was used to query formulation prescribed, usage patterns, length of use, symptom relief, and side effect profile. Descriptive statistics were calculated. Of 45 gynecologic cancer patients prescribed MM, 89% were receiving chemotherapy; 56% were undergoing primary treatment. MM was used for a median of 5.2 months (range 0.6–25.4). Over 70% of patients reported improvement in nausea/vomiting, compared to 36% of patients using MM for pain relief (p = 0.02). Of 41 patients with follow-up information, 71% found MM improved at least one symptom. Among a small sample of gynecologic cancer patients prescribed MM for symptom management, self-reported follow-up indicated symptom relief for the majority of patients and minimal therapy-related side effects. This data can prove useful for counseling gynecologic cancer patients on the efficacy and side effects of MM.

1 January 2019 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
JLJung Mo Lee
Jung Mo Lee
TKTaehee Kim
Taehee Kim
EKEun Young Kim
Eun Young Kim
AKArum Kim
Arum Kim
DLDong Ki Lee
Dong Ki Lee
YCYoon Soo Chang
Yoon Soo Chang
Lee JM, et al. Yonsei Med J. 2019 Nov;60(11):1005-1012. https://doi.org/10.3349/ymj.2019.60.11.1005